3654 results for «382»

Filter By

3654 results

Navigating complexities in multivalvular heart disease: risk stratification, intervention timing, and advanced imaging

01 Feb 2025 – From PCR Imaging Valves Madrid 2025

This session explores the challenges of managing mixed and multiple valvular heart diseases, focusing on risk stratification, treatment decisions, and transcatheter intervention timing. Experts discuss assessing and treating aortic and mitral paravalvular leaks, as well as managing mitral annular calcification, using case studies to guide optimal...

Navigating complexities in multivalvular heart disease

TAVI in bicuspid anatomy

08 Feb 2025 – From PCR Tokyo Valves 2025

Discover the key insights from this PCR Tokyo Valves 2025 session focused on TAVI in bicuspid anatomy. Learn why TAVI for bicuspid aortic stenosis (AS) shows comparable long-term outcomes to tricuspid AS in registry data, and understand the importance of patient selection, precise valve sizing, and...

TAVI in bicuspid anatomy

M-TEER difficult situation: small mitral valves, P2 prolapse & leaflet degeneration

08 Feb 2025 – From PCR Tokyo Valves 2025

Explore a series of challenging cases in Mitral Transcatheter Edge-to-Edge Repair (M-TEER), highlighting the versatility and adaptability of this technique. Discover how M-TEER can be successfully applied in patients with extremely small mitral valves, P2 prolapse supported by chordae from the posterior papillary muscle, wide prolapse...

M-TEER difficult situation: small mitral valves, P2 prolapse & leaflet degeneration

TAVI complications cases - Part 1

08 Feb 2025 – From PCR Tokyo Valves 2025

Dive into the world of TAVI complications in this comprehensive session. Explore a range of challenging cases, including bailout implantation of an embolized self-expandable valve, ascending aortic dissection, coronary embolization, cardiac tamponade, and annular rupture. Gain insights into the management strategies and specialized techniques employed to...

TAVI complications cases: embolized valve, aortic dissection & coronary embolisation

Late-Breaking Trial session

08 Feb 2025 – From PCR Tokyo Valves 2025

Discover the latest insights from pivotal studies in this PCR Tokyo Valves 2025 LBT session. Explore early feasibility updates from the AltaValve trial, in-hospital outcomes comparing surgical vs. percutaneous intervention in aortic stenosis with coronary artery disease from the JROAD-DPC data, and procedural results from the...

Late-Breaking Trial session

M-TEER for primary mitral regurgitation

08 Feb 2025 – From PCR Tokyo Valves 2025

In this PCR Tokyo Valves 2025 session on M-TEER for primary mitral regurgitation, gain valuable insights starting with an overview of current TEER devices. Benefit from four case studies that highlight the features of these devices, explore strategies to prevent mitral regurgitation recurrence post-TEER, and delve...

M-TEER for primary mitral regurgitation

M-TEER around the world

08 Feb 2025 – From PCR Tokyo Valves 2025

Explore the latest insights and advancements in the field of Mitral Transcatheter Edge-to-Edge Repair (M-TEER) from around the world. Discover a new anatomical risk score for predicting procedural outcomes, two-year outcomes from the MiCLASP study, the impact of regurgitant volume to left atrial volume ratio on...

M-TEER around the world

TAVI complications: hemolytic anemia, prosthetic valve endocarditis & stroke

08 Feb 2025 – From PCR Tokyo Valves 2025

Gain valuable insights into the management of complications associated with Transcatheter Aortic Valve Implantation (TAVI). Discover the latest evidence on hemolytic anemia, the predictive value of the hemoglobin to creatinine ratio, outcomes of transcarotid TAVI, a case study on prosthetic valve endocarditis, the role of diastolic...

TAVI complications: hemolytic anemia, prosthetic valve endocarditis & stroke

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?

02 Sep 2024

Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

Luis Ortega-Paz

Author

Luis Ortega-Paz
POPular PAUSE TAVI

Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials

14 Nov 2021

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Vijay Kunadian

Author

Vijay Kunadian
Best of #AHA21 Scientific sessions

Evidence base: current data on TAVI durability and long-term outcomes

18 Jun 2026

This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.

Tanja Rudolph

Author

Tanja Rudolph
Georges El Hachem

Author

Georges El Hachem
Evidence base: current data on durability

ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines

29 Aug 2021

There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...

Dr. Mirvat Alasnag

Author

Mirvat Alasnag

Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)

30 Oct 2024

Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.

Author

Ali Nazmi Calik
Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
Didn’t find what you were looking for?